

# Pillar 3 Regulatory Disclosures

For the quarterly period ended March 31, 2022

# March 31, 2022 Pillar 3 Regulatory Disclosures

### **TABLE OF CONTENTS**

Glossary of Acronyms and Terms	2
Introduction	4
Report Overview	4
Scope of Application	5
Risk Governance	5
Capital Structure and Adequacy	6
Capital Structure	8
Credit Risk	11
Credit Risk Exposure  Counterparty Credit Risk-Related Disclosures  Credit Risk Mitigation	15
Securitization	16
Equities (Non-Trading)	18
Market Risk	19
Appendix 1 - Citizens Financial Group, Inc. Pillar 3 Regulatory Disclosures Matrix	20
Appendix 2 - Forward-Looking Statements	23

# March 31, 2022 Pillar 3 Regulatory Disclosures

# **GLOSSARY OF ACRONYMS AND TERMS**

The following is a list of common acronyms and terms we regularly use in our financial reporting:

-	
AACL	Adjusted Allowance for Credit Losses
ACL	Allowance for Credit Losses: Allowance for Loan and Lease Losses plus Allowance for Unfunded Lending Commitments
AFS	Available for Sale
AOCI	Accumulated Other Comprehensive Income (Loss)
ВНС	Bank Holding Company
Board or Board of Directors	The Board of Directors of Citizens Financial Group, Inc.
CBNA	Citizens Bank, National Association
CCAR	Comprehensive Capital Analysis and Review
CCMI	Citizens Capital Markets, Inc.
CECL	Current Expected Credit Losses (ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments)
CET1	Common Equity Tier 1
CET1 capital ratio	Common Equity Tier 1 capital divided by total risk-weighted assets as defined under the U.S. Basel III Standardized approach
Citizens, CFG, the Company, we, us, or our	Citizens Financial Group, Inc. and its Subsidiaries
COVID-19 pandemic	Coronavirus Disease 2019 Pandemic
CRA	Community Reinvestment Act
CSA	Credit Support Annex
CVA	Credit Valuation Adjustment
Dodd-Frank Act	The Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010
FDIA	Federal Deposit Insurance Act
FHLB	Federal Home Loan Bank
FHA	Federal Housing Administration
FHLMC	Federal Home Loan Mortgage Corporation
FNMA	Federal National Mortgage Association
Form 10-K	Annual Report on Form 10-K
Form 10-Q	Quarterly Report on Form 10-Q
FR Y-9C	Regulatory Financial Statements for Bank Holding Companies
FRB or Federal Reserve	Board of Governors of the Federal Reserve System and, as applicable, Federal Reserve Bank(s)
GAAP	Accounting Principles Generally Accepted in the United States of America
GNMA	Government National Mortgage Association
HSBC	HSBC Bank U.S.A., N.A.
HSBC transaction	Acquisition of HSBC East Coast branches and national online deposit business
Investors	Investors Bancorp, Inc.
JMP	JMP Group LLC
MBS	Mortgage-Backed Securities
Mid-Atlantic	District of Columbia, Delaware, Maryland, New Jersey, New York, Pennsylvania, Virginia, and West Virginia
Midwest	Illinois, Indiana, Michigan, and Ohio
Modified AACL Transition	The Day-1 CECL adoption entry booked to ACL plus 25% of subsequent CECL ACL reserve build

# March 31, 2022 Pillar 3 Regulatory Disclosures

Modified CECL Transition	The Day-1 CECL adoption entry booked to retained earnings plus 25% of subsequent CECL ACL reserve build
MSRs	Mortgage Servicing Rights
New England	Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont
NRSRO	Nationally Recognized Statistical Ratings Organizations
occ	Office of the Comptroller of the Currency
ОТС	Over the Counter
Parent Company	Citizens Financial Group, Inc. (the Parent Company of Citizens Bank, National Association and other subsidiaries)
RWA	Risk-Weighted Assets
SCB	Stress Capital Buffer
SSFA	Simplified Supervisory Formula Approach
Tailoring Rules	Rules establishing risk-based categories for determining prudential standards for large U.S. and foreign banking organizations, consistent with the Dodd-Frank Act, as amended by the Economic Growth, Regulatory Relief and Consumer Protection Act
Tier 1 capital ratio	Tier 1 capital, which includes Common Equity Tier 1 capital plus non-cumulative perpetual preferred equity that qualifies as additional tier 1 capital, divided by total risk-weighted assets as defined under the U.S. Basel III Standardized approach
Tier 1 leverage ratio	Tier 1 capital, which includes Common Equity Tier 1 capital plus non-cumulative perpetual preferred equity that qualifies as additional tier 1 capital, divided by quarterly adjusted average assets as defined under the U.S. Basel III Standardized approach
Total capital ratio	Total capital, which includes Common Equity Tier 1 capital, tier 1 capital and allowance for credit losses and qualifying subordinated debt that qualifies as tier 2 capital, divided by total risk-weighted assets as defined under the U.S. Basel III Standardized approach
USDA	United States Department of Agriculture
VA	United States Department of Veterans Affairs
VaR	Value at Risk

### March 31, 2022 Pillar 3 Regulatory Disclosures

#### **INTRODUCTION**

Citizens Financial Group, Inc. is one of the nation's oldest and largest financial institutions with \$192.1 billion in assets as of March 31, 2022. Headquartered in Providence, Rhode Island, we offer a broad range of retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations and institutions. We help our customers reach their potential by listening to them and by understanding their needs in order to offer tailored advice, ideas and solutions. In Consumer Banking, we provide an integrated experience that includes mobile and online banking, a full-service customer contact center and, including the acquisition of Investors, the convenience of approximately 3,300 ATMs and more than 1,200 branches in 14 states and the District of Columbia. Consumer Banking products and services include a full range of banking, lending, savings, wealth management and small business offerings. In Commercial Banking, we offer a broad complement of financial products and solutions, including lending and leasing, deposit and treasury management services, foreign exchange, interest rate and commodity risk management solutions, as well as loan syndication, corporate finance, merger and acquisition, and debt and equity capital markets capabilities. More information is available at www.citizensbank.com.

On February 18, 2022, CBNA completed the acquisition of HSBC East Coast branches and national online deposit business. The transaction extends our physical presence and adds customers in several attractive markets, accelerating our national expansion strategy. The transaction includes 66 locations in the New York City metropolitan area, 9 locations in the Mid-Atlantic/Washington D.C. area, and 5 locations in Southeast Florida.

On April 6, 2022, Citizens completed the acquisition of all outstanding shares of Investors for a combination of stock and cash. The acquisition enhances Citizens' banking franchise, adding an attractive middle market, small business and consumer customer base while building our physical presence in the Mid-Atlantic region with the addition of 154 branches located in the greater New York City and Philadelphia metropolitan areas and across New Jersey.

#### Report Overview

We produce this report quarterly to update market participants regarding risk-based capital and risk exposures as required under U.S. regulations that interpret global regulatory standards known as "Basel III." The U.S. banking regulators refer to this ongoing requirement as "Pillar 3 Regulatory Disclosures." This report provides information on our capital structure, risk exposures, risk assessment processes, RWA and overall capital adequacy, including information on the methodologies used to calculate RWA. This report is unaudited and should be read in conjunction with our 2021 Form 10-K and Form 10-Q for the period ended March 31, 2022, which include important information on risk management policies and practices, and our March 31, 2022 FR Y-9C. Appendix 1 of this report contains references to specific sections of our 2021 Form 10-K and Form 10-Q for the period ended March 31, 2022 to facilitate location of applicable information.

This report may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement that does not describe historical or current facts is a forward-looking statement, as discussed further in Appendix 2 of this report.

### March 31, 2022 Pillar 3 Regulatory Disclosures

#### Scope of Application

CFG is a "standardized approach" and "AOCI opt-out" reporting institution under the U.S. Basel III Standardized framework. Our basis for consolidation used for regulatory financial statement reporting purposes is the same as the basis used for our financial statements prepared under GAAP. Refer to Note 1 in our 2021 Form 10-K and Note 1 in our Form 10-Q for the period ended March 31, 2022 for more information on the basis for consolidation for financial reporting purposes.

#### Restrictions on transfers between CFG and CBNA

CFG is a financial holding company and a BHC, regulated and supervised by the FRB. The OCC is the primary regulator and supervisor for CBNA. Applicable statutes and regulations that may pertain either to CFG, CBNA, and all entities as affiliates may restrict transfers of funds and capital between these entities.

Sections 23A and 23B of the Federal Reserve Act and FRB Regulation W are the primary restrictors of lending, borrowing, and otherwise transacting business between affiliates. Refer to "Business - Regulation and Supervision - Transactions with Affiliates and Insiders" in our 2021 Form 10-K for a discussion of these regulations. Restrictions on the payment of dividends and other capital distributions weigh most heavily on CBNA. The FRB expects a BHC to act as a "source of strength" to each individual subsidiary bank it owns by providing capital and liquidity as needed. Consistent with this view, bank regulators ensure that a bank does not return capital to the BHC in a manner that would undermine its overall "safety and soundness." Therefore, CBNA is subject to specific qualitative and quantitative tests and examinations that may restrict it from paying dividends or otherwise returning capital to the Parent Company. For more information, refer to "Business - Regulation and Supervision" in our 2021 Form 10-K for an overview of the general controls and restrictions imposed on distributions of capital by CBNA and "Management's Discussion and Analysis of Financial Condition and Results of Operations - Capital and Regulatory Matters" in our Form 10-Q for the period ended March 31, 2022 for details of CBNA's status versus its applicable regulatory minimums.

CFG and CBNA are subject to capital adequacy and liquidity standards. If CFG or CBNA fail to meet these standards, it could have an adverse effect on our financial condition and operations. Refer to "Risk Factors - Risks Related to Regulations Governing Our Industry" in our 2021 Form 10-K.

#### **RISK GOVERNANCE**

We are committed to maintaining a strong, integrated, and proactive approach to the management of all risks to which we are exposed in pursuit of our business objectives. A key aspect of our Board's responsibility as the main decision making body is setting our risk appetite to ensure that the levels of risk that we are willing to accept in the attainment of our strategic business and financial objectives are clearly understood.

To enable our Board to carry out its objectives, it has delegated authority for risk management activities, as well as governance and oversight of those activities, to a number of Board and executive management level risk committees. The Executive Risk Committee, chaired by the Chief Risk Officer, is responsible for oversight of risk across the enterprise and actively considers our inherent material risks, analyzes our overall risk profile and seeks confirmation that the risks are being appropriately identified, assessed and mitigated. Reporting to the Executive Risk Committee are the following committees covering specific areas of risk: Compliance and Operational Risk Committee, Model Risk Committee, Credit Policy Committee, Asset Liability Committee, Business Initiatives Review Committee, and the Conduct and Ethics Committee.

Refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Risk Governance" in our 2021 Form 10-K for additional information on our risk governance practices.

### March 31, 2022 Pillar 3 Regulatory Disclosures

#### **CAPITAL STRUCTURE AND ADEQUACY**

#### Capital Structure

We manage capital to ensure consistency with all applicable regulations and statutes, as well as with Board-approved internal policies established to ensure that the quantity and quality of current and projected capital will be adequate in relation to the risks that we assume across all lines of business. Refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Capital and Regulatory Matters" in our Form 10-Q for the period ended March 31, 2022 for additional information. As of March 31, 2022, our regulatory capital instruments consisted of common equity that qualifies as CET1 capital, preferred stock that qualifies as additional tier 1 capital, and subordinated debt that qualifies as tier 2 capital. Table 1 below presents our regulatory capital instruments for the period ended March 31, 2022.

Table 1	
(in millions, except share and per share data)	
Common Equity	
Common stock and related surplus, net of treasury stock	\$14,109
\$.01 par value, 1,000,000,000 shares authorized, 572,153,923 shares issued, and 423,031,985 shares outstanding	
Preferred Equity	
Preferred stock and related surplus	
\$25.00 par value, 100,000,000 shares authorized, liquidation preference of \$1,000 per share:	
Series B: 300,000 shares issued and outstanding	296
Series C: 300,000 shares issued and outstanding	297
Series D: 300,000 <sup>(1)</sup> shares issued and outstanding	293
Series E: 450,000 <sup>(2)</sup> shares issued and outstanding	437
Series F: 400,000 shares issued and outstanding	395
Series G: 300,000 shares issued and outstanding	296
Total preferred stock and related surplus	\$2,014
Qualifying Subordinated Debt	
4.150% fixed-rate subordinated debt, due September 2022 (non-qualifying \$168) <sup>(3)</sup>	_
3.750% fixed-rate subordinated debt, due July 2024 (non-qualifying \$54) <sup>(3)</sup>	36
4.023% fixed-rate subordinated debt, due October 2024 (non-qualifying \$10) <sup>(3)</sup>	7
4.350% fixed-rate subordinated debt, due August 2025 (non-qualifying \$53) <sup>(3)</sup>	80
4.300% fixed-rate subordinated debt, due December 2025 (non-qualifying \$135) <sup>(3)</sup>	202
4.300% fixed-rate reset subordinated debt, due February 2031	135
3.750% fixed-rate reset subordinated debt, due February 2031	69
4.350% fixed-rate reset subordinated debt, due February 2031	60
2.638% fixed-rate subordinated debt, due September 2032	551
Total qualifying subordinated debt	\$1,140

<sup>(1)</sup> Represented by 12,000,000 depositary shares each representing a 1/40th interest and a liquidation preference of \$25 per depositary share.

Our regulatory adjustments and deductions from CET1 capital are presented in Table 2 below and include goodwill and intangible assets net of associated deferred tax liabilities. The U.S. Basel III capital rules also require additional capital deductions for MSRs, certain deferred tax assets ("DTAs") and investments in the capital of unconsolidated financial institutions.

<sup>(2)</sup> Represented by 18,000,000 depositary shares each representing a 1/40th interest and a liquidation preference of \$25 per depositary share.
(3) Per the U.S. Basel III Standardized rules, tier 2 capital instrument eligibility for inclusion in regulatory capital is phased out 20% per year, beginning five years prior to the applicable maturity date.

### March 31, 2022 Pillar 3 Regulatory Disclosures

Under the U.S. Basel III rules, the CET1 deduction threshold for MSRs, certain DTAs and investments in the capital of unconsolidated financial institutions is 25%. As of March 31, 2022, we did not meet the threshold for these additional capital deductions. MSRs or certain DTAs not deducted from CET1 capital are assigned a 250% risk weight and investments in the capital of unconsolidated financial institutions not deducted from CET1 capital are assigned an exposure category risk weight.

In reaction to the COVID-19 pandemic, the FRB and the other federal banking regulators adopted a final rule relative to regulatory capital treatment of ACL under CECL. This rule allows electing banking organizations to delay the estimated impact of CECL on regulatory capital for a two-year period ending December 31, 2021, followed by a three-year transition period ending December 31, 2024. The three-year transition period will phase-in the aggregate amount of capital benefit provided during the initial two-year delay. On December 31, 2021, the aggregate amount of capital benefit was \$384 million. The reduction in the capital benefit in 2022 is \$96 million, or 6 basis points.

As an "AOCI opt-out" institution, we are not required to recognize in regulatory capital the impacts of net unrealized gains and losses included within AOCI for debt securities that are available for sale or held to maturity, accumulated net gains and losses on cash flow hedges and certain defined benefit pension plan assets.

As of March 31, 2022, CET1 capital represented 77% of our total regulatory capital. Table 2 below presents our regulatory capital composition for the period ended March 31, 2022.

Table 2	
(in millions)	
Common stock and related surplus, net of treasury stock	\$14,109
Retained earnings	8,209
Accumulated other comprehensive loss	(2,258)
Total common shareholders' equity	20,060
Exclusions:	
Modified CECL transitional amount	288
Net unrealized (gains)/losses recorded in accumulated other comprehensive income, net of tax:	
Debt securities	1,236
Derivatives	675
Unamortized net periodic benefit costs	347
Deductions:	
Goodwill	(7,232)
Deferred tax liability associated with goodwill	387
Other intangible assets	(117)
Deferred tax assets that arise from tax loss and credit carryforwards	(1)
Total common equity tier 1 capital	15,643
Qualifying preferred stock	2,014
Total tier 1 capital	17,657
Qualifying subordinated debt <sup>(1)</sup>	1,140
Allowance for credit losses	1,878
Exclusions from tier 2 capital:	
Modified AACL transitional amount	(374)
Adjusted allowance for credit losses	1,504
Total tier 2 capital	2,644
Total capital	\$20,301

<sup>(1)</sup> Non-qualifying subordinated debt excluded from regulatory capital is \$420 million.

### March 31, 2022 Pillar 3 Regulatory Disclosures

#### **Capital Adequacy Process**

Our assessment of capital adequacy begins with our board-approved risk appetite and risk management framework. This framework provides for the identification, measurement and management of material risks. For more information on our capital adequacy risk appetite and risk management framework, refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Capital and Regulatory Matters" in our 2021 Form 10-K.

Under the FRB's Tailoring Rules, Category IV firms, such as us, are subject to biennial supervisory stress testing and are exempt from company-run stress testing and related disclosure requirements. The FRB supervises Category IV firms on an ongoing basis, including evaluation of the capital adequacy and capital planning processes during off-cycle years. Annually, the FRB requires us to submit a capital plan approved by our board of directors or one of its committees. Our annual capital plan is due each year in April. We submitted our 2022 Capital Plan to the FRB on April 4, 2022. For more information, see the "Tailoring of Prudential Requirements" section in Item 1 of our 2021 Form 10-K.

We develop a capital plan and conduct routine capital management activities in compliance with internal limits and operating targets that we establish for each regulatory capital ratio. The intent of these limits and targets is to meet both regulatory and market expectations, while also ensuring an efficient return to shareholders. We set these internal limits and targets to comply with the U.S. Basel III minimums, which include applicable buffer requirements. Refer to the related discussion in the "Stress Capital Buffer" section of this report.

Regulations relating to capital planning, regulatory reporting, stress testing and capital buffer requirements applicable to firms like us are presently subject to rule-making and potential further guidance and interpretation by the applicable federal regulators. We will continue to evaluate the impact of these and any other prudential regulatory changes, including their potential resultant changes in our regulatory and compliance costs and expenses. For additional information, see "Business - Regulation and Supervision" in our 2021 Form 10-K and "Management's Discussion and Analysis of Financial Condition and Results of Operations - Capital and Regulatory Matters" in our Form 10-Q for the period ended March 31, 2022.

### March 31, 2022 Pillar 3 Regulatory Disclosures

Table 3 below presents the U.S. Basel III Standardized capital ratios for CFG and CBNA as of March 31, 2022. All ratios remained well above the U.S. Basel III minimums. Refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Capital and Regulatory Matters" in our Form 10-Q for the period ended March 31, 2022 for additional information related to the calculation of our capital ratios.

Table 3					
Citizens Financial Group, Inc.					
	Ratio	Required Minimum plus FDIA Required Well-Capitaliz Required SCB for Non-Leverage Minimum for Purposes of Pron Ratios <sup>(1)</sup> Corrective Action <sup>(2)</sup>			
CET1 capital	9.7 %	7.9 %	N/A		
Tier 1 capital	10.9	9.4	N/A		
Total capital	12.5	11.4	N/A		
Tier 1 leverage	9.6	4.0	N/A		
	Citizens E	Bank, National Association			
	Ratio	Required Minimum plus FDIA Required Well-Capitalized Required CCB for Non-Leverage Minimum for Purposes of Promp io Ratios <sup>(1)</sup> Corrective Action			
CET1 capital	10.7 %	7.0 %	6.5 %		
Tier 1 capital	10.7	8.5	8.0		
Total capital	12.3	10.5	10.0		
Tier 1 leverage	9.4	4.0	5.0		

<sup>(1)</sup> The minimum non-leverage capital ratio includes our stress capital buffer of 3.4% and CBNA includes the capital conservation buffer of 2.5%.

Table 4 below presents the composition of our RWA for the period ended March 31, 2022. Refer to "Schedule HC-R - Part II Risk-Weighted Assets" in our March 31, 2022 FR Y-9C report for details on adjustments and deductions to calculate total RWA.

Table 4		
(in millions)		
Corporate exposures	\$78,382	
Other retail exposures	42,725	
Other assets	15,099	
Residential mortgage exposures	13,703	
Mortgage backed securities - FNMA & FHLMC	3,348	
Equities	2,809	
Letters of credit	1,867	
Securitization exposures	1,415	
Past due loans (excluding Sovereigns, Guarantees & Home Lending)	551	
High volatility commercial real estate	530	
Exposures to sovereign entities	193	
Exposures to depository institutions, foreign banks, and credit unions	58	
Cleared transactions	24	
Default fund contributions	1	
Total standardized RWA for credit risk exposure	\$160,705	
Market risk	1,154	
Total RWA	\$161,859	

Refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Capital and Regulatory Matters" in our Form 10-Q for the period ended March 31, 2022 for more information regarding capital ratios and the capital adequacy process.

<sup>(2)</sup> Prompt corrective action provisions apply only to our insured depository institution, CBNA.

### March 31, 2022 Pillar 3 Regulatory Disclosures

#### Stress Capital Buffer

We are subject to the firm-specific risk sensitive Stress Capital Buffer ("SCB"). The SCB is based on the projected losses under the supervisory severely adverse scenario of each firm subject to CCAR plus four quarters of planned common stock dividends, subject to a floor of 2.5% Under the SCB framework, the FRB will not object to capital plans on quantitative grounds and each firm is required to maintain capital ratios above the sum of its minimum and SCB requirements to avoid restrictions on capital distributions and discretionary bonus payments.

For Category IV firms, like us, the SCB will be re-calibrated with each biennial supervisory stress test and updated annually to reflect our planned common stock dividends. In addition, Category IV firms may elect to participate in the supervisory stress test and receive an updated SCB requirement in a year in which they are not subject to the supervisory stress test. Our SCB requirement effective October 1, 2021, through September 30, 2022, is 3.4%. We are subject to the 2022 supervisory stress test conducted by the FRB and expect to receive an updated SCB from the FRB later this year. On March 22, 2022, the FRB approved our application to acquire Investors and indicated that it will use the 2023 stress test to recalculate our SCB to incorporate the effects of the Investors acquisition into our capital requirements.

Based on our current SCB, the effective minimum risk-based capital requirements applicable to us are:

- 7.9% CET1 capital to RWA (minimum 4.5% plus 3.4% SCB);
- 9.4% Tier 1 capital (CET1 plus Additional Tier 1 capital) to RWA (minimum 6% plus 3.4% SCB); and
- 11.4% Total capital (Tier 1 capital plus Tier 2 capital) to RWA (minimum 8% plus 3.4% SCB).

As of March 31, 2022, the lowest of our three risk-based capital ratios less applicable minimum was 4.5%, well above our SCB of 3.4%. As a result, we are not subject to payout ratio limitations on our capital distributions or certain discretionary bonus payments. Eligible retained income<sup>(1)</sup> at March 31, 2022 was \$1.1 billion, consisting of net income for the preceding four quarters, net of any distributions and associated tax effects not already in net income.

<sup>(1)</sup> Eligible retained income is defined by regulations as the greater of (1) net income for the four preceding calendar quarters, net of any distributions and associated tax effects not already reflected in net income, and (2) the average of a banking organization's net income over the preceding four quarters.

### March 31, 2022 Pillar 3 Regulatory Disclosures

#### **CREDIT RISK**

#### Credit Risk Exposure

Table 5 below presents total credit risk exposures for our loans, loans held for sale, leases, contractual commitments to extend credit, and letters of credit for the period ended March 31, 2022. This table is categorized by counterparty types for both commercial and retail loan products.

Table 5	
(in millions)	
Commercial and industrial	\$90,891
Commercial real estate	21,890
Leases	1,634
Total commercial	114,415
Residential mortgages	26,709
Home equity	32,424
Automobile	14,439
Education	13,753
Other retail	20,485
Total retail	107,810
Total	\$222,225

Refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Risk Governance - Credit Risk" in our 2021 Form 10-K for more information on credit risk governance.

Our loan and lease credit related accounting policies are presented in Note 6 in our 2021 Form 10-K and Note 5 in our Form 10-Q for the period ended March 31, 2022.

Our investment securities portfolio includes U.S. Treasury and agency securities, agency mortgage-backed securities, non-agency mortgage-backed securities and asset-backed securities. The most important element management relies on when assessing credit risk for U.S. Treasury and agency securities and agency mortgage-backed securities is the guarantee of the Federal Government or one of its agencies. When applicable, we consider geography as a factor when managing our investments in securities issued by state and political subdivisions. We assess the credit risk for non-agency mortgage-backed securities and asset-backed securities based on senior to subordinated credit support levels and an analysis of the bond's underlying collateral characteristics. As a secondary measure, the non-agency mortgage-backed securities consider ratings by NRSRO, but not solely relied upon, to determine the creditworthiness of the issuance.

Refer to Note 3 and Note 9 in our Form 10-Q for the period ended March 31, 2022 and the "Counterparty Credit Risk-Related Disclosures" section of this report for more information on our credit risk exposures related to investment securities and derivatives. Refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Net Interest Income" in our Form 10-Q for the period ended March 31, 2022 for average balances of our loans and leases and investment securities. The average credit risk exposure related to our OTC derivatives for the quarter ended March 31, 2022 was \$1.4 billion.

Refer to Note 12 in our Form 10-Q for the period ended March 31, 2022 for more information on the credit risk exposure related to our off-balance sheet commitments (including contractual commitments to extend credit and letters of credit). The average credit risk exposure associated with our off-balance sheet credit commitments and letters of credit for the quarter ended March 31, 2022 was \$89 billion.

Table 6 below presents the geographic distribution of our loans, loans held for sale, leases, credit commitments and letters of credit. The geographic distribution presented in this table uses the address of the customer as the basis for classification. Amounts reported as "Other" include credit to customers outside of the Mid-Atlantic,

### March 31, 2022 Pillar 3 Regulatory Disclosures

Midwest, and New England regions, as well as certain exposures that we do not manage on a geographic basis, such as merchant point-of-sale financing.

Table 6					
	As of March 31, 2022				
(in millions)	Mid-Atlantic	Midwest	New England	Other	Total
Commercial and industrial	\$30,932	\$10,524	\$18,328	\$31,107	\$90,891
Commercial real estate	7,424	1,668	3,203	9,595	21,890
Leases	520	313	123	678	1,634
Total commercial	38,876	12,505	21,654	41,380	114,415
Residential mortgages	14,306	1,226	5,130	6,047	26,709
Home equity	13,779	3,472	14,158	1,015	32,424
Automobile	4,712	2,298	1,975	5,454	14,439
Education	4,629	1,641	2,225	5,258	13,753
Other retail	6,387	1,846	4,208	8,044	20,485
Total retail	43,813	10,483	27,696	25,818	107,810
Total	\$82,689	\$22,988	\$49,350	\$67,198	\$222,225

Our gross commercial and retail charge-offs for the quarter-to-date period ended March 31, 2022 were \$14 million and \$87 million, respectively. We measure the ACL reserve based on groups of loans with similar risk characteristics and it is not disaggregated on the basis of impairment method.

Refer to Note 5 in our Form 10-Q for the period ended March 31, 2022 for more information on ACL including ACL balances and related year-to-date charge-off information. ACL and AACL are the same for the period ended March 31, 2022 since we did not have credit loss allowances on AFS debt securities or purchased credit deteriorated assets.

Table 7 below presents our loans and leases past due 90 days and on nonaccrual and loans past due 90 days and still accruing.

Table 7						
		As of March 31, 2022				
(in millions)	90+ Days Past Due and Accruing	90+ Days Past Due and Nonaccruing	Total 90+ Days Past Due			
Commercial and industrial	\$13	\$20	\$33			
Commercial real estate	_	10	10			
Leases	5	1	6			
Total commercial	18	31	49			
Residential mortgages <sup>(1)</sup>	792	214	1,006			
Home equity	_	202	202			
Automobile	_	14	14			
Education	2	10	12			
Other retail	14	18	32			
Total retail	808	458	1,266			
Total	\$826	\$489	\$1,315			

<sup>(1) 90+</sup> days past due and accruing includes \$792 million of loans fully or partially guaranteed by the FHA, VA, and USDA.

## March 31, 2022 Pillar 3 Regulatory Disclosures

Table 8 below presents our nonaccrual loans and leases categorized by geographic area.

Table 8					
	As of March 31, 2022				
(in millions)	Mid-Atlantic	Midwest	New England	Other	Total
Commercial and industrial	\$81	\$4	\$27	\$88	\$200
Commercial real estate	1	1	9	_	11
Leases	-	_	_	1	1
Total commercial	82	5	36	89	212
Residential mortgages <sup>(1)</sup>	155	22	44	22	243
Home equity	121	26	75	17	239
Automobile	14	8	5	25	52
Education	7	2	3	11	23
Other retail	10	4	5	1	20
Total retail	307	62	132	76	577
Total	\$389	\$67	\$168	\$165	\$789

<sup>(1)</sup> Loans fully or partially guaranteed by the FHA, VA and USDA are classified as accruing.

Table 9 below presents a summary of our nonaccrual loans and leases with and without a related allowance.

Table 9					
	As of March 31, 2022				
(in millions)	Nonaccrual Loans With a Related Allowance	Nonaccrual Loans Without a Related Allowance	Total Recorded Investment in Nonaccrual Loans		
Commercial and industrial	\$169	\$31	\$200		
Commercial real estate	10	1	11		
Leases	1	_	1		
Total commercial	180	32	212		
Residential mortgages <sup>(1)</sup>	64	179	243		
Home equity	51	188	239		
Automobile	42	10	52		
Education	20	3	23		
Other retail	19	1	20		
Total retail	196	381	577		
Total	\$376	\$413	\$789		

<sup>(1)</sup> Loans fully or partially guaranteed by the FHA, VA and USDA are classified as accruing.

## March 31, 2022 Pillar 3 Regulatory Disclosures

Table 10 below presents a summary of our loans, loans held for sale and leases by remaining maturity.

		Table 10					
	As of March 31, 2022						
(in millions)	One Year or Less <sup>(1)</sup>	Over One Year Through Five Years	Over Five Years Through Fifteen Years	Over Fifteen Years	Total		
Commercial and industrial	\$7,677	\$32,713	\$5,512	\$43	\$45,945		
Commercial real estate	3,639	9,804	814	11	14,268		
Leases	120	921	488	_	1,529		
Total commercial	11,436	43,438	6,814	54	61,742		
Residential mortgages	1,929	63	1,217	22,597	25,806		
Home equity	250	74	1,219	10,721	12,264		
Automobile	500	7,124	6,815	_	14,439		
Education	202	1,323	8,394	3,387	13,306		
Other retail	3,187	2,245	25	107	5,564		
Total retail	6,068	10,829	17,670	36,812	71,379		
Total	\$17,504	\$54,267	\$24,484	\$36,866	\$133,121		

<sup>(1)</sup> Loans held for sale are included in One Year or Less category.

Table 11 below presents a summary of our credit commitments and letters of credit by remaining maturity.

Table 11					
	As of March 31, 2022				
(in millions)	One Year or Less	Greater than One Year	Total		
Credit commitments					
Commercial and industrial	\$11,047	\$31,922.16	\$42,969		
Commercial real estate	1,046	6,576	7,622		
Leases	85	20	105		
Total commercial	12,178	38,518	50,696		
Residential mortgages	903	_	903		
Home equity	374	19,786	20,160		
Automobile	_	_	_		
Education	447	_	447		
Other retail	13,781	1,140	14,921		
Total retail	15,505	20,926	36,431		
Total credit commitments	27,683	59,444	87,127		
Letters of credit	962	1,015	1,977		
Total credit commitments and letters of credit	\$28,645	\$60,459	\$89,104		

Refer to Note 3 in our Form 10-Q for the period ended March 31, 2022 for a summary of securities by contractual maturity and "Schedule HC-R - Part II Risk-Weighted Assets" in our March 31, 2022 FR Y-9C for a summary of OTC derivative notional amounts by remaining maturity.

### March 31, 2022 Pillar 3 Regulatory Disclosures

#### Counterparty Credit Risk-Related Disclosures

Counterparty exposure arises primarily from the OTC derivative transactions in our customer and institutional derivative portfolios. The amount of this exposure depends on the value of underlying market factors (e.g., interest and foreign exchange rates), which can be volatile and uncertain in nature. Counterparty exposure also arises (to a lesser extent) from our securities lending and borrowing activities, which includes entering into repurchase agreements.

The customer derivative portfolio consists of interest rate swap agreements and option contracts transacted to meet the financing needs of our customers. We transact swap agreements and interest rate options agreements to effectively minimize our market risk associated with the customer derivative products. The customer derivative portfolio also includes foreign exchange forward agreements and option contracts entered into on behalf of customers for the purpose of hedging exposure related to cash orders, loans, and deposits denominated in foreign currencies. We also enter into commodity swaps and option contracts on behalf of customers in our oil and gas vertical primarily, to mitigate commodity price volatility. Customer trades are primarily unsecured and are not subject to daily margin or posting of financial collateral. We commonly execute these trades concurrently with new loan transactions, with any business collateral received from a counterparty applied to both the derivative and loan. Accordingly, the underwriting process for establishing customer derivative credit limits is equivalent to the process used for corporate loan exposure. We establish these limits based on potential future exposure using stochastic models developed by F.I.S., a third party risk management software solution provider. The models utilize Monte Carlo methods consistent with industry practice and are subject to risk governance for model risk management and validation. We manage the credit risk of our customer derivative positions by diversifying our positions among various counterparties and in certain cases, transferring the counterparty credit risk related to interest rate swaps to third parties using risk participation agreements. When measuring the fair value of our customer derivative portfolio for GAAP financial reporting purposes, we include a CVA that reflects the credit quality of the swap counterparty, as well as factors in our own credit quality. For more information on our valuation methodologies, refer to Note 20 in our 2021 Form 10-K.

Residential loan derivatives include loan commitments that allow residential mortgage customers to lock in the interest rate on a residential mortgage while the loan undergoes the underwriting process. We use forward sales contracts to protect the value of residential mortgage loans and loan commitments that we underwrite for future sale to investors in the secondary market. We also hedge the fair market value movements of certain MSRs using various interest rate derivative contracts.

The institutional derivative portfolio primarily consists of interest rate swap agreements used to hedge the interest rate risk associated with our loans and financing liabilities (e.g., borrowed funds, deposits, etc.). Institutional swaps and swaps executed to mitigate the market risk associated with our customer derivative products and residential loan derivatives include bilateral trades with dealers and cleared trades with central counterparties. These trades must comply with daily margin requirements where we post financial collateral based on pre-defined "posting thresholds". Posting thresholds represent the amount of exposure that counterparties are willing to accept on an unsecured basis. We post collateral only when the market value of any outstanding swaps exceeds that threshold. Changes in our own creditworthiness do not generally have an impact on the amount of collateral posted given zero thresholds have become the market convention. Bilateral trades with dealers are subject to counterparty credit limits that cover replacement costs and potential changes in market value based on a ten day close out period. Cleared trades with central counterparties are subject to counterparty credit limits for initial margin requirements where we post collateral, but where the collateral is operationally commingled with initial margin owed to other clients of the clearing broker.

Our repurchase agreements are typically short-term transactions (i.e., overnight), but they may be extended to longer terms-to-maturity (not to exceed 270 days). We fully collateralize such transactions and account for them as secured borrowings in our financial statements. We establish counterparty credit limits to monitor our overcollateralized position, which represents the difference between the market value of the collateral pledged and the amount we borrow. When permitted by GAAP, we offset short-term receivables with short-term payables associated with our reverse repurchase agreements.

### March 31, 2022 Pillar 3 Regulatory Disclosures

On a daily basis we monitor counterparty credit exposures for counterparties with an established CSA to ensure appropriately sized collateral levels to cover risk. We manage collateral received from third parties and held pursuant to the terms of the governing CSA agreement for the counterparty, in either a tri-party custodial, segregated or an omnibus account. We negotiate the collateral requirements on each established CSA and primarily include cash in the form of U.S. Dollars.

Refer to Note 9 in our Form 10-Q for the period ended March 31, 2022 for fair value of our derivative transactions on both a gross and net basis. The net basis presented represents the impact of enforceable master netting agreements as well as collateral paid and received.

Refer to Note 3 in our Form 10-Q for the period ended March 31, 2022 for information on our repurchase agreements and Note 13 in our Form 10-Q for the period ended March 31, 2022 for the fair value of our repurchase agreements.

#### **Credit Risk Mitigation**

We limit our credit risk mitigation that is recognized for the purposes of reducing capital requirements to implicit and explicit credit guarantees provided by the U.S. Government. We do not use collateral as a source of credit risk mitigation for the purposes of reducing capital requirements. Table 12 below presents our total exposure covered by guarantees and the risk-weighted amounts associated with each exposure.

Table 12					
(dollars in millions)	As of March 31, 2022				
Guarantor	Guaranteed Exposure Amount	RWA	RW %		
FNMA & FHLMC	\$16,754	\$3,351	20 %		
Federal Housing Administration (FHA)	1,193	239	20		
Small Business Administration (SBA)	72	14	20		
Federal Family Education Loan Program (FFELP) where 97% of exposure is guaranteed	31	6	20		
Federal Family Education Loan Program (FFELP) where 98% of exposure is guaranteed	10	2	20		
Veteran Affairs (VA)	80	16	20		
United States Department of Agriculture (USDA)	53	11	20		
Total implicit guarantees	\$18,193	\$3,639	20 %		
US Treasury & GNMA securities	\$9,863	\$-	0 %		
SBA Paycheck Protection Program	417	_	0		
Export/Import	5	_	0		
Total explicit guarantees	\$10,285	\$-	0 %		

### **SECURITIZATION**

A securitization exposure is a transaction in which the credit risk of the underlying exposure transfers to third parties and is separated into two or more tranches. The performance of a securitization depends upon the performance of the underlying exposures or reference assets, all or substantially all of which are financial exposures. We participate in the securitization market as an investor and a lender in traditional securitization exposures; however, not as an originator or sponsor. We invest in securitization exposures of third party issued non-agency MBS, collateralized loan obligations and other asset-backed securities. Other asset-backed securities are collateralized by loans that we sold to a third-party sponsored VIE and we provided financing to the purchaser for a portion of the sales price of the asset-backed securities. We also may act as a securitization lender by entering into asset-backed securitization loans with third party sponsored special purpose entities that are designed to meet client needs for long-term financing of assets or working capital. We calculate the regulatory

### March 31, 2022 Pillar 3 Regulatory Disclosures

capital requirement for securitization exposure in accordance with the U.S. Basel III Standardized approach. RWA for securitization exposures is determined using SSFA. The SSFA framework considers our seniority in the securitization structure and risk factors inherent in the underlying assets. For more information on our securities portfolio, refer to Note 3 in our Form 10-Q for the period ended March 31, 2022.

We do not apply credit risk mitigation to our securitized exposures and do not have exposure to securitization guarantors. We do not have synthetic securitization exposure and all securitization exposures are held on our balance sheet.

#### Risk Management

We manage the risks related to securitization positions in accordance with the investment, credit, and interest rate risk management policies. Refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Risk Governance" in our 2021 Form 10-K for more information on our credit risk and interest rate risk (i.e., non-trading risk) governance. For each securitization position, we perform due diligence on the credit worthiness of each position prior to entering into that position. Our due diligence procedures provide a comprehensive understanding of the features that would materially affect the performance of a securitization, and are commensurate with the complexity of each securitization position held.

Table 13 below presents our exposures receiving securitization capital treatment by collateral type and capital treatment method.

	Table	13				
	As of March 31, 2022					
	SSFA 1250% Total					al
(in millions)	Exposure	RWA	Exposure	RWA	Exposure	RWA
Asset-backed securitization lending	\$4,704	\$941	\$-	\$-	\$4,704	\$941
Asset-backed securitization investment	1,962	392	_	_	1,962	392
Private label MBS	412	82	-	-	412	82
Total securitization exposure	\$7,078	\$1,415	\$-	\$-	\$7,078	\$1,415

Table 14 below presents our exposures receiving securitization capital treatment by method and risk weighting.

	Table	14				
	As of March 31, 2022					
	SSF	SSFA 1250%		Total		
(in millions)	Exposure	RWA	Exposure	RWA	Exposure	RWA
Securitizations by risk weight:						
= 0% to <= 20%	\$7,078	\$1,415			\$7,078	\$1,415
> 20% to <= 50%	_	_			_	_
> 50% to <= 100%	_	_			_	_
> 100% to <= 1250%	_	_			_	_
Total securitizations	\$7,078	\$1,415	\$-	\$-	\$7,078	\$1,415
Re-securitizations by risk weight:						
= 0% to <= 20%	\$-	\$-	\$-	\$-	\$-	\$-
Total re-securitizations	\$-	\$-	\$-	\$-	\$-	\$-
Total securitization exposure	\$7,078	\$1,415	\$-	\$-	\$7,078	\$1,415

### March 31, 2022 Pillar 3 Regulatory Disclosures

### **Accounting Policies**

For information on our accounting policy for investments in securitized assets (i.e., "investments in debt securities") see Note 4 in our 2021 Form 10-K.

#### **EQUITIES (NON-TRADING)**

We hold equity securities to fulfill requirements of membership and participation in U.S. banking and payments systems. CBNA holds stock in the FRB and the FHLB. Our equity holdings include fund and non-fund equities and immaterial amounts of stock. The non-fund equities use the simple risk-weight approach and primarily consist of investments in community projects in conjunction with our commitment to the communities in which we operate. These investments also fulfill specific requirements imposed by the CRA as implemented by the U.S. regulatory agencies. In addition to CRA investments, we invest in renewable wind energy projects, providing benefits from returns generated by government incentives plus other tax attributes that come with ownership. We also have invested amounts in fund-related equity investments, consisting primarily of money market mutual fund investments, and separate account bank owned life insurance. The underlying assets of separate account bank owned life insurance consist primarily of treasuries, mortgaged-backed securities, and bonds. The fund-related equity investments use the full look-through approach to determine risk weight.

Our accounting policy for equity securities (i.e., "other investment securities") is presented in Note 4 in our 2021 Form 10-K. We present methodologies for measuring the fair value of equity securities in Note 20 in our 2021 Form 10-K. The carrying value of our CRA investments are included in the other assets line in "Financial Statements - Consolidated Balance Sheets" in our Form 10-Q for the period ended March 31, 2022. Separate account bank-owned life insurance is included in the bank-owned life insurance line within the "Financial Statements - Consolidated Balance Sheets" in our Form 10-Q for the period ended March 31, 2022. Table 15 below presents our equity exposures and the risk-weighted amounts associated with each exposure.

Table 15				
	As of March 31, 2022			
(dollars in millions)	Exposure	RWA	RW %	
Federal Reserve stock	\$577	\$-	0 %	
FHLB stock	18	4	20	
Investments in Non-Fund Equities:				
CRA	2,215	2,215	100	
Renewable energy	417	417	100	
Other non-fund equities	21	21	100	
Investment in Fund Equities:				
Separate account bank owned life insurance	264	110	42	
Money market mutual fund investments	100	20	20	
Other fund equities	22	22	100	
Total	\$3,634	\$2,809		

### March 31, 2022 Pillar 3 Regulatory Disclosures

#### **MARKET RISK**

#### Non-Trading Risk

We are exposed to market risk as a result of non-trading banking activities. This market risk is substantially composed of interest rate risk, as we have no commodity risk and de minimis direct currency and equity risk. We also have market risk related to capital markets loan originations, as well as the valuation of our MSRs.. Refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Market Risk - Non-Trading Risk" in our Form 10-Q for the period ended March 31, 2022 for more information on our exposure to interest rate risk. Refer to Note 9 in our Form 10-Q for the period ended March 31, 2022 for more information on our hedging policies and our processes for monitoring hedge effectiveness.

#### **Trading Risk**

We are exposed to market risk primarily through client facilitation activities including derivatives and foreign exchange products as well as underwriting and market making activities. Exposure is created as a result of changes in interest rates and related basis spreads and volatility, foreign exchange rates, equity prices, and credit spreads on a select range of interest rates, foreign exchange, commodities, equity securities, corporate bonds and secondary loan instruments. These securities underwriting and trading activities are conducted through CBNA, CCMI and JMP. While we do not always meet the applicable reporting threshold of the Market Risk Rule, we nevertheless continually adhere to the Market Risk Rule covering our trading activities.

As of March 31, 2022, our market risk RWA was \$1.2 billion, reflecting general market rate/price risk and specific risk. We do not model our specific risk through the VaR based process and thus we calculate a specific risk add-on under a standardized measurement method. We do not calculate incremental risk or comprehensive risk, as we take a standardized specific risk add-on, and we do not participate in correlation trading related activities.

For further discussion related to market risk governance, risk measurements, VaR methodology and validation, and regulatory capital, refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Risk Governance" in our 2021 Form 10-K and "Management's Discussion and Analysis of Financial Condition and Results of Operations - Market Risk" in our Form 10-Q for the period ended March 31, 2022.

# March 31, 2022 Pillar 3 Regulatory Disclosures

### APPENDIX 1 - CITIZENS FINANCIAL GROUP, INC. PILLAR 3 REGULATORY DISCLOSURES MATRIX

The disclosures required by the U.S. Basel III Standardized rule<sup>(1)</sup> are listed below. Most of these disclosures have been included in other financial reporting documents, and some in this report. This matrix provides a reference to the location of each required disclosure.

<sup>(1)</sup> Code of Federal Regulations, Part 217 - Capital Adequacy of Bank Holding Companies, Savings and Loan Holding Companies, and State Member Banks (Regulation Q).

Disclosure Requirement	Description	Pillar 3 reference	1Q22 10-Q	2021 10-K
1. Scope of application	Name of the top corporate entity	pg. 4	MD&A - Introduction	
	Descriptions of differences in basis for consolidating entities	pg. 5	Note 1 - Basis of Presentation	Note 1 - Basis of Presentation
	Restrictions on transfers of funds or total capital within the group	pg. 5		
	Aggregate amount of surplus capital of insurance subsidiaries	N/A		
	Aggregate amount of total capital that is less than minimum capital	N/A		
2. Capital structure	Terms and conditions of capital instruments	pg. 6		
	Capital composition	pg. 7		
3. Capital adequacy	Capital adequacy assessment process	pg. 8	MD&A - Capital and Regulatory Matters	MD&A - Capital and Regulatory Matters
	Capital ratios	pg. 9	MD&A - Capital and Regulatory Matters	MD&A - Capital and Regulatory Matters
	Risk-weighted assets by exposure type	pg. 9		
	Market risk-weighted assets	pg. 9		
4. Stress capital buffer	Stress capital buffer	pg. 10	MD&A - Capital and Regulatory Matters	MD&A - Capital and Regulatory Matters
	Calculated eligible retained income	pg. 10		
	Limitations of distributions and discretionary bonus payments	pg. 10		
5. Credit risk	Credit risk exposures	pg. 11		
	Policies and practices	pg. 5	Note 5 - Allowance for Credit Losses, Nonaccruing Loans and Leases, and Concentrations of Credit Risk	MD&A - Risk Governance
	Loans and related commitments	pg. 11	Note 4 - Loans and Leases & Note 12 - Commitments and Contingencies	Note 5 - Loans and Leases & Note 19 - Commitments and Contingencies
	Debt securities	pg. 11	Note 3 - Securities	Note 4 - Securities

# March 31, 2022 Pillar 3 Regulatory Disclosures

Disclosure Requirement	Description	Pillar 3 reference	1Q22 10-Q	2021 10-K
	OTC derivatives	pg. 11	Note 9 - Derivatives & Note 13 - Fair Value Measurements	Note 14 - Derivatives
	Geographic distribution of exposures	pg. 12		
	Allowance disaggregated on the basis of impairment methodology	pg. 12		
	Charge-offs during the period	pg. 12	Note 5 - Allowance for Credit Losses, Nonaccruing Loans and Leases, and Concentrations of Credit Risk	Note 6 - Allowance for Credit Losses, Nonperforming Assets, and Concentrations of Credit Risk
	Nonaccrual loans by industry or counterparty	pg. 13	Note 5 - Allowance for Credit Losses, Nonaccruing Loans and Leases, and Concentrations of Credit Risk	Note 6 - Allowance for Credit Losses, Nonperforming Assets, and Concentrations of Credit Risk
	Past due loans by product	pg. 12	Note 5 - Allowance for Credit Losses, Nonaccruing Loans and Leases, and Concentrations of Credit Risk	Note 6 - Allowance for Credit Losses, Nonperforming Assets, and Concentrations of Credit Risk
	Nonaccrual loans by geography	pg. 13		
	Reconciliation of changes in allowance	pg. 12	Note 5 - Allowance for Credit Losses, Nonaccruing Loans and Leases, and Concentrations of Credit Risk	Note 6 - Allowance for Credit Losses, Nonperforming Assets, and Concentrations of Credit Risk
	Remaining maturity of loans and loans held for sale	pg. 14		
	Remaining maturity of credit commitments and letters of credit	pg. 14		
6. Counterparty credit risk-related exposures	Policies and practices	pg. 15	Note 9 - Derivatives	Note 14 - Derivatives
	Counterparty risk exposure	pg. 15	Note 3 - Securities, Note 9 - Derivatives & Note 13 - Fair Value Measurements	Note 20 - Fair Value Measurements

# March 31, 2022 Pillar 3 Regulatory Disclosures

Disclosure Requirement	Description	Pillar 3 reference	1Q22 10-Q	2021 10-K
	Credit derivatives purchased and sold	N/A		
7. Credit risk mitigation	Policies and processes	pg. 16		
	Exposures covered by eligible financial collateral	N/A		
	Exposures covered by guarantees/credit derivatives and related risk-weighted assets	pg. 16		
8. Securitization	Policies and practices	pg. 16		
	SPEs and affiliated entities	N/A		
	Accounting policies for securitization activities	pg. 18		
	Exposures securitized by the bank and resecuritizations	N/A		
	Securitization exposures by collateral type	pg. 17		
	Securitization exposures by risk weight	pg. 17		
9. Equities not subject to the market risk rule	Policies and practices	pg. 18	Note 7 - Variable Interest Entities	
	Amortized cost and fair value by type/nature and public versus nonpublic	pg. 18	Note 13 - Fair Value Measurements	
	Realized and unrealized gains (losses)	N/A		
	Capital requirements	pg. 18		
10. Interest rate risk for non-trading activities	Nature, assumptions and frequency of measurement	pg. 19	MD&A - Market Risk	MD&A - Market Risk
	Earnings sensitivity to rate movements	pg. 19	MD&A - Market Risk	MD&A - Market Risk

### March 31, 2022 Pillar 3 Regulatory Disclosures

#### **APPENDIX 2 - FORWARD-LOOKING STATEMENTS**

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements regarding potential future share repurchases and future dividends as well as the potential effects of the COVID-19 disruption on our business, operations, financial performance and prospects, are forward-looking statements. Also, any statement that does not describe historical or current facts is a forward-looking statement. These statements often include the words "believes," "expects," "anticipates," "estimates," "intends," "plans," "goals," "targets," "initiatives," "potentially," "probably," "projects," "outlook," "guidance" or similar expressions or future conditional verbs such as "may," "will," "should," "would," and "could."

Forward-looking statements are based upon the current beliefs and expectations of management, and on information currently available to management. Our statements speak as of the date hereof, and we do not assume any obligation to update these statements or to update the reasons why actual results could differ from those contained in such statements in light of new information or future events. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. While there is no assurance that any list of risks and uncertainties or risk factors is complete, important factors that could cause actual results to differ materially from those in the forward-looking statements include the following, without limitation:

- Negative economic and political conditions that adversely affect the general economy, housing prices, the job
  market, consumer confidence and spending habits which may affect, among other things, the level of nonaccrual
  assets, charge-offs and provision expense;
- The rate of growth in the economy and employment levels, as well as general business and economic conditions, and changes in the competitive environment;
- Our ability to implement our business strategy, including the cost savings and efficiency components, and achieve our financial performance goals, including through the integration of Investors and the HSBC branches;
- The COVID-19 disruption and its effects on the economic and business environments in which we operate;
- Our ability to meet heightened supervisory requirements and expectations;
- Liabilities and business restrictions resulting from litigation and regulatory investigations;
- Our capital and liquidity requirements under regulatory capital standards and our ability to generate capital internally or raise capital on favorable terms;
- The effect of changes in interest rates on our net interest income, net interest margin and our mortgage originations, mortgage servicing rights and mortgages held for sale;
- Changes in interest rates and market liquidity, as well as the magnitude of such changes, which may reduce
  interest margins, impact funding sources and affect the ability to originate and distribute financial products in the
  primary and secondary markets;
- The effect of changes in the level of checking or savings account deposits on our funding costs and net interest margin;
- Financial services reform and other current, pending or future legislation or regulation that could have a negative effect on our revenue and businesses;
- A failure in or breach of our operational or security systems or infrastructure, or those of our third party vendors or other service providers, including as a result of cyber-attacks;
- An inability to complete the Investors acquisition, or changes in the current anticipated timeframe, terms or manner of such acquisition;
- Greater than expected costs or other difficulties related to the integration of our business and that of Investors and the relevant HSBC branches;
- The inability to retain existing Investors or HSBC clients and employees following the closing of the Investors and HSBC branch acquisitions;

### March 31, 2022 Pillar 3 Regulatory Disclosures

- The occurrence of any event change or other circumstance that could give rise to the right of one or both parties to terminate the agreement to acquire Investors; and
- Management's ability to identify and manage these and other risks.

In addition to the above factors, we also caution that the actual amounts and timing of any future common stock dividends or share repurchases will be subject to various factors, including our capital position, financial performance, risk-weighted assets, capital impacts of strategic initiatives, market conditions and regulatory and accounting considerations, as well as any other factors that our Board of Directors deems relevant in making such a determination. Therefore, there can be no assurance that we will repurchase shares from or pay any dividends to holders of our common stock, or as to the amount of any such repurchases or dividends. Further, statements about the effects of the COVID-19 disruption on our business, operations, financial performance and prospects may constitute forward-looking statements and are subject to the risk that the actual impacts may differ, possibly materially, from what is reflected in those forward-looking statements due to factors and future developments that are uncertain, unpredictable and in many cases beyond our control, including the scope and duration of the pandemic, actions taken by governmental authorities in response to the pandemic, and the direct and indirect impact of the pandemic on our customers, third parties and us. Statements about the Investors and HSBC branch acquisitions also constitute forward-looking statements and are subject to the risk that actual results could be materially different from those expressed in those statements, including if the Investors transaction is not consummated in a timely manner or at all, or if integration of the acquisitions is more costly or difficult than expected.

More information about factors that could cause actual results to differ materially from those described in the forward-looking statements can be found in the "Risk Factors" section in Part I, Item 1A. of our Annual Report on Form 10-K for the year ended December 31, 2021.